Pharmaceutical intermediates
Ubrogepant Intermediates
4 pharmaceutical intermediates for Ubrogepant. Indication: Migraine Disorders.
About Ubrogepant
- Originator
- Abbvie
- Indication
- Migraine Disorders
- Approved Date
- 12/23/2019
- DS/DP
- 11/10/2031
Available intermediates
4 intermediates currently listed for Ubrogepant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (S)-1'-(tert-butyl)-3-chloro-5,7-dihydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one | 1455358-14-1 | / | / |
| 1-(tert-butyl)-3-((5-chloro-3-(hydroxymethyl)pyridin-2-yl)methyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one | 1455358-11-8 | / | / |
| Ubrogepant Intermediate | 1375541-21-1 | / | / |
| (3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidine-3-aminium 4-nitrobenzoate | 1456803-37-4 | / | / |
Other programs under U
Building toward Ubrogepant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →